Radiotherapy & Combi in Metastatic Melanoma (CombiRT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02392871
Recruitment Status : Recruiting
First Posted : March 19, 2015
Last Update Posted : June 28, 2018
Melanoma Institute Australia
Information provided by (Responsible Party):
Australia and New Zealand Melanoma Trials Group

Brief Summary:

The purpose of this study is to investigate the side effects and safety, and effectiveness of combining dabrafenib and trametinib with radiotherapy.

Previous and ongoing clinical trials have demonstrated the effectiveness and safety of combining both dabrafenib and trametinib compared with dabrafenib alone. This has led to the approval for the use of both drugs in combination in people with metastatic melanoma with the BRAF mutation. Melanoma that has spread to other parts of the body may also benefit from radiotherapy to help reduce symptoms from melanoma. Previous studies have shown that melanoma may be sensitive to radiotherapy and that it can help to improve quality of life.

The intention of the CombiRT study is to establish if dabrafenib, trametinib and radiotherapy combined is a safe and effective treatment for metastatic melanoma.

Condition or disease Intervention/treatment Phase
Metastatic Melanoma Radiation: Palliative radiotherapy Drug: Dabrafenib and trametinib (combination) Phase 1 Phase 2

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-label, Single-arm, Phase I/II, Multicentre Study to Evaluate the Safety and Efficacy of the Combination of Dabrafenib, Trametinib and Palliative Radiotherapy in Patients With Unresectable (Stage IIIc) and Metastatic (Stage IV) BRAF V600E/K Mutation-positive Cutaneous Melanoma
Actual Study Start Date : May 2015
Estimated Primary Completion Date : June 2019
Estimated Study Completion Date : June 2020

Arm Intervention/treatment
Experimental: Radiotherapy

Palliative radiotherapy in combination with dabrafenib and trametinib Eligible subjects are patients who have been on dabrafenib and trametinib for more than 2 weeks, as the current standard management for advanced stage melanoma.

Palliative RT will be delivered to symptomatic or bulky (>2cm) soft tissue, nodal or bony metastases concurrently with dabrafenib and trametinib. Up to 3 areas of disease can be irradiated at the same time.

Following RT, dabrafenib and trametinib alone will be continued until disease progression according to RECIST 1.1 criteria.

Radiation: Palliative radiotherapy
Drug: Dabrafenib and trametinib (combination)
Patients should be taking dabrafenib and trametinib for at least 2 weeks prior to enrolment into the study.

Primary Outcome Measures :
  1. Toxicity profile for patients receiving dabrafenib and trametinib in combination with RT, by measuring adverse events and radiotherapy associated toxicities. [ Time Frame: 0-12 months ]

Secondary Outcome Measures :
  1. Patients' pain using a visual analog scale (questionnaire) [ Time Frame: 0-12 months ]
  2. Overall disease response by measuring progression free survival and overall survival. [ Time Frame: 0-12 months ]
  3. Local treatment response in the irradiated index lesion(s). [ Time Frame: 0-12 months ]
  4. Time to local progression in the irradiated index lesion(s). [ Time Frame: 0-12 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. ≥18 years of age.
  2. Signed written informed consent.
  3. Histologically confirmed cutaneous melanoma that is either Stage IIIC (unresectable) or Stage IV (metastatic), and determined to be BRAF V600E/K mutation-positive as determined by a BRAF mutation assay.

    Note: For Stage IIIC disease, the decision that the disease is unresectable should be formally endorsed by the melanoma multidisciplinary tumour board of the local institution.

  4. Have received dabrafenib and trametinib for 2 weeks or more prior to enrolment in the study (i.e. first fraction of palliative RT), and is still continuing with dabrafenib and trametinib.
  5. Symptomatic or bulky (greater than 2 cm in diameter) soft tissue, nodal or bony metastases requiring palliative RT.
  6. Have measurable disease according to RECIST 1.1 criteria. Note: patients with bony metastases that are not measurable by RECIST 1.1 criteria are allowed in this study.
  7. All anti-cancer treatment-related toxicities (except alopecia and laboratory values as listed on Table 1 in protocol) must be less than or equal to (≤) Grade 1 according to the Common Terminology Criteria for Adverse Events version 4 (CTCAE version 4.03; NCI, 2009) at the time of study enrolment.
  8. Able to swallow and retain oral medication and must not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowels.
  9. Women of childbearing potential must have a negative serum pregnancy test within 7 days prior to enrolment and agree to use effective contraception, from 14 days prior to enrolment throughout the treatment period, and for 4 months after the last dose of study treatment.
  10. An Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  11. Adequate baseline organ function (as defined in Table 1 in protocol).

Exclusion Criteria:

  1. Treatment with Ipilimumab or any other anti-CTLA-4 monoclonal antibody therapy within the past 4 weeks.
  2. Treatment with anti-PD-1 or anti-PD-L1 monoclonal antibody therapy within the past 4 weeks.
  3. Known ocular or primary mucosal melanoma.
  4. Four (4) or more lesions requiring palliative RT at the time of study enrolment.
  5. Symptomatic brain metastases or those treated < 3 months previously.
  6. Clear evidence of systemic disease progression on dabrafenib and trametinib.
  7. Systemic anti-cancer treatment (chemotherapy, immunotherapy, biologic therapy, vaccine therapy, or investigational treatment) within the last 4 weeks. Prior interferon treatment in the adjuvant setting is allowed.

    Note: Tamoxifen and aromatase inhibitors are allowed in the adjuvant setting of breast cancer.

  8. Current use of a prohibited medication (list of prohibited medications in protocol).
  9. History of malignancy other than disease under study within 3 years of study enrolment with exceptions below, or any malignancy with confirmed activating RAS mutation.

    Note: Prospective RAS testing is not required. However, if the results of previous RAS testing are known, they must be used in assessing eligibility.

    Exception: Subjects who have been disease-free for 3 years, or subjects with a history of completely resected non-melanoma skin cancer.

  10. Any serious or unstable pre-existing medical conditions (aside from malignancy exceptions specified above), psychiatric disorders, or other conditions that could interfere with the subject's safety, obtaining informed consent, or compliance with study procedures.
  11. A history of known Human Immunodeficiency Virus (HIV).
  12. A history or evidence of cardiovascular risk including any of the following:

    • A QT interval corrected for heart rate using the Bazett's formula (QTcB) ≥ 480 msec;
    • A history or evidence of current clinically significant uncontrolled arrhythmias;
    • A history of acute coronary syndromes (including myocardial infarction or unstable angina), coronary angioplasty, or stenting within 6 months prior to enrolment;
    • A history or evidence of current ≥ Class II congestive heart failure as defined by the New York Heart Association (NYHA) guidelines;
    • Patients with intra-cardiac defibrillators;
    • Abnormal cardiac valve morphology (≥ grade 2) documented by echocardiogram (subjects with grade 1 abnormalities [i.e., mild regurgitation/stenosis] can be entered on study). Subjects with moderate valvular thickening should not be entered on study; g. Treatment refractory hypertension defined as a blood pressure of systolic> 140 mmHg and/or diastolic > 90 mm Hg which cannot be controlled by anti-hypertensive therapy; h. Known cardiac metastases.
  13. A history of retinal vein occlusion (RVO).
  14. Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to the study treatments, their excipients, and/or dimethyl sulfoxide (DMSO).
  15. Pregnant or nursing females.
  16. Previous RT to the same lesion or area due to receive the current course of palliative RT.

    Note: patients who had previous RT to other areas are eligible to the study if the previous RT was completed more than 8 weeks prior.

  17. A history of autoimmune diseases which are known to increase radiation toxicity, including systemic lupus erythematosus and scleroderma.
  18. Genetic syndromes exhibiting increased radiosensitivity (e.g. ataxia telangiectasia).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02392871

Contact: ANZMTG Coordinator 612 9911 7200

Australia, New South Wales
St Vincent's Hospital Recruiting
Darlinghurst, New South Wales, Australia, 2010
Contact: Ashley Douglas   
Principal Investigator: Gerald Fogarty, MBBS         
Sub-Investigator: Anthony Joshua, MBBS         
Westmead Hospital Recruiting
Sydney, New South Wales, Australia, 2145
Contact: Tracy Pearl-Larsson   
Principal Investigator: Tim Wang, MBBS         
Sub-Investigator: Matteo Carlino, MBBS         
Australia, Queensland
Princess Alexandra Hospital Recruiting
Brisbane, Queensland, Australia, 4102
Contact: Adrienne See   
Principal Investigator: Matthew Foote, MBBS         
Sponsors and Collaborators
Australia and New Zealand Melanoma Trials Group
Melanoma Institute Australia
Principal Investigator: Tim Wang Westmead Hospital

Responsible Party: Australia and New Zealand Melanoma Trials Group Identifier: NCT02392871     History of Changes
Other Study ID Numbers: ANZMTG 02.14
First Posted: March 19, 2015    Key Record Dates
Last Update Posted: June 28, 2018
Last Verified: June 2018

Keywords provided by Australia and New Zealand Melanoma Trials Group:
Metastatic melanoma
Palliative radiotherapy

Additional relevant MeSH terms:
Nevi and Melanomas
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action